EP-104GI

Small molecule

EEupraxia Pharmaceuticals Inc.

EP-104GI is one of 43 small molecule programs targeting Eosinophilic Esophagitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eosinophilic EsophagitisActive, not recruiting

Eosinophilic EsophagitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Eosinophilic Esophagitis

#DrugCompanyPhaseTrials

Flovent

PParatek Pharmaceuticals Inc

Approved

5 2

Prevacid

Cinqair

2 4

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

10 5

Tezspire

AstraZeneca

Phase 3

1 6

Fasenra

AstraZeneca

Phase 3

1 7

Xolair

Roche

Phase 2

2 8

Asmanex

Novartis

Phase 2

1 9

Velsipity

Pfizer

Phase 2

1 10

Lialda

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Eosinophilic Esophagitis

NCT05608681

Clinical

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

Recruiting·EEupraxia Pharmaceuticals Inc.·Phase 1/2·NCT05608681·117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EP-104GI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EP-104GI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EP-104GI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eupraxia Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: EEupraxia Pharmaceuticals Inc.

EP-104GI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

References

Drug Info

Quick Facts

Related News